Structure Therapeutics Inc
GPCR64.940USD
+2.490+3.99%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
3.94BMarket Cap
LossP/E TTM
More Details of Structure Therapeutics Inc Company
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Structure Therapeutics Inc Info
Ticker SymbolGPCR
Company nameStructure Therapeutics Inc
IPO dateFeb 03, 2023
CEOStevens (Raymond)
Number of employees163
Security typeDepository Receipt
Fiscal year-endFeb 03
Address601 Gateway Blvd Suite 900
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504571978
Websitehttps://structuretx.com/
Ticker SymbolGPCR
IPO dateFeb 03, 2023
CEOStevens (Raymond)
Company Executives of Structure Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Xichen Lin, Ph.D.
Dr. Xichen Lin, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
49.23K
+885.53%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
41.17K
--
Ms. Yingli Ma
Ms. Yingli Ma
Chief Technology Officer
Chief Technology Officer
27.34K
+271.74%
Mr. Angus C. Russell
Mr. Angus C. Russell
Independent Director
Independent Director
--
--
Ms. Sharon Tetlow
Ms. Sharon Tetlow
Independent Director
Independent Director
--
--
Mr. Jun Yoon
Mr. Jun Yoon
Chief Financial Officer, Co-Founder
Chief Financial Officer, Co-Founder
--
--
Dr. Joanne Waldstreicher, M.D.
Dr. Joanne Waldstreicher, M.D.
Independent Director
Independent Director
--
--
Mr. Eric L. Dobmeier, J.D.
Mr. Eric L. Dobmeier, J.D.
Independent Director
Independent Director
--
--
Dr. Blai Coll, M.D., Ph.D.
Dr. Blai Coll, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Raymond Stevens, Ph.D.
Dr. Raymond Stevens, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Xichen Lin, Ph.D.
Dr. Xichen Lin, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
49.23K
+885.53%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
41.17K
--
Ms. Yingli Ma
Ms. Yingli Ma
Chief Technology Officer
Chief Technology Officer
27.34K
+271.74%
Mr. Angus C. Russell
Mr. Angus C. Russell
Independent Director
Independent Director
--
--
Ms. Sharon Tetlow
Ms. Sharon Tetlow
Independent Director
Independent Director
--
--
Mr. Jun Yoon
Mr. Jun Yoon
Chief Financial Officer, Co-Founder
Chief Financial Officer, Co-Founder
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Wellington Management Company, LLP
9.95%
Avoro Capital Advisors LLC
7.46%
Janus Henderson Investors
6.43%
Fidelity Management & Research Company LLC
6.20%
Deep Track Capital LP
6.10%
Other
63.86%
Shareholders
Shareholders
Proportion
Wellington Management Company, LLP
9.95%
Avoro Capital Advisors LLC
7.46%
Janus Henderson Investors
6.43%
Fidelity Management & Research Company LLC
6.20%
Deep Track Capital LP
6.10%
Other
63.86%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
31.99%
Hedge Fund
25.69%
Investment Advisor
20.19%
Venture Capital
4.37%
Individual Investor
2.51%
Research Firm
1.66%
Private Equity
1.65%
Bank and Trust
0.23%
Pension Fund
0.03%
Other
11.68%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
395
54.88M
90.49%
-15.39M
2025Q2
379
59.75M
103.74%
-16.58M
2025Q1
381
62.21M
108.14%
-12.86M
2024Q4
357
66.09M
115.26%
-5.81M
2024Q3
330
65.93M
115.14%
-2.45M
2024Q2
298
63.40M
110.86%
+11.42M
2024Q1
239
45.01M
96.54%
-1.29M
2023Q4
210
43.42M
93.57%
+9.41M
2023Q3
125
33.38M
93.24%
+15.44M
2023Q2
64
17.69M
49.41%
+2.82M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Wellington Management Company, LLP
6.88M
11.94%
-915.41K
-11.75%
Jun 30, 2025
Janus Henderson Investors
4.57M
7.94%
+217.81K
+5.00%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.73M
8.21%
-1.07M
-18.47%
Jun 30, 2025
Deep Track Capital LP
5.13M
8.91%
+1.03M
+25.22%
Jun 30, 2025
BVF Partners L.P.
1.66M
2.89%
-109.30K
-6.17%
Aug 11, 2025
Baker Bros. Advisors LP
2.51M
4.36%
+2.15M
+593.86%
Jun 30, 2025
Casdin Capital, LLC
1.23M
2.13%
+525.00K
+75.00%
Jun 30, 2025
RA Capital Management, LP
1.52M
2.63%
--
--
Jun 30, 2025
Millennium Management LLC
1.22M
2.12%
+429.90K
+54.41%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Roundhill GLP-1 & Weight Loss ETF
5.49%
TrueShares Technology, AI & Deep Learning ETF
3.59%
WisdomTree BioRevolution Fund
1.7%
Virtus LifeSci Biotech Clinical Trials ETF
1.02%
ALPS Medical Breakthroughs ETF
0.81%
American Century Focused Dynamic Growth ETF
0.37%
ProShares Ultra Nasdaq Biotechnology
0.26%
Invesco Nasdaq Biotechnology ETF
0.2%
SPDR S&P Emerging Markets Small Cap ETF
0.18%
Fidelity Fundamental Small-Mid Cap ETF
0.18%
View more
Roundhill GLP-1 & Weight Loss ETF
Proportion5.49%
TrueShares Technology, AI & Deep Learning ETF
Proportion3.59%
WisdomTree BioRevolution Fund
Proportion1.7%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.02%
ALPS Medical Breakthroughs ETF
Proportion0.81%
American Century Focused Dynamic Growth ETF
Proportion0.37%
ProShares Ultra Nasdaq Biotechnology
Proportion0.26%
Invesco Nasdaq Biotechnology ETF
Proportion0.2%
SPDR S&P Emerging Markets Small Cap ETF
Proportion0.18%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.18%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Structure Therapeutics Inc?
The top five shareholders of Structure Therapeutics Inc are:
Wellington Management Company, LLP holds 6.88M shares, accounting for 11.94% of the total shares.
Janus Henderson Investors holds 4.57M shares, accounting for 7.94% of the total shares.
Fidelity Management & Research Company LLC holds 4.73M shares, accounting for 8.21% of the total shares.
Deep Track Capital LP holds 5.13M shares, accounting for 8.91% of the total shares.
BVF Partners L.P. holds 1.66M shares, accounting for 2.89% of the total shares.
Wellington Management Company, LLP holds 6.88M shares, accounting for 11.94% of the total shares.
Janus Henderson Investors holds 4.57M shares, accounting for 7.94% of the total shares.
Fidelity Management & Research Company LLC holds 4.73M shares, accounting for 8.21% of the total shares.
Deep Track Capital LP holds 5.13M shares, accounting for 8.91% of the total shares.
BVF Partners L.P. holds 1.66M shares, accounting for 2.89% of the total shares.
What are the top three shareholder types of Structure Therapeutics Inc?
The top three shareholder types of Structure Therapeutics Inc are:
Wellington Management Company, LLP
Avoro Capital Advisors LLC
Janus Henderson Investors
Wellington Management Company, LLP
Avoro Capital Advisors LLC
Janus Henderson Investors
How many institutions hold shares of Structure Therapeutics Inc (GPCR)?
As of 2025Q3, 395 institutions hold shares of Structure Therapeutics Inc, with a combined market value of approximately 54.88M, accounting for 90.49% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -13.25%.
What is the biggest source of revenue for Structure Therapeutics Inc?
In --, the -- business generated the highest revenue for Structure Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
